Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia
NCT04110964Phase 1Unknown
- Sponsor
- Libella Gene Therapeutics
- Start
- Sep 2019
- Primary completion
- Dec 2020
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AAV-hTERT in critical limb ischemia (CLI), sponsored by Libella Gene Therapeutics. Primary endpoint: Incidence of adverse events at 12 months. Status: unknown.
02
Drugs
AAV-hTERT
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT04110964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04110964.